10th CAR-TCR Post Conference Presentation

The CAR-TCR Therapy Landscape Report provides the most up-to-date intelligence on the rapidly evolving field of cell therapies. Built on insights from Beacon Cell Therapy, this analysis covers the entire CAR and TCR ecosystem — from drug assets and trial activity to deals and emerging technologies.

Key Highlights from the Report

• Expanding Pipeline:
  • CAR therapies grew from 3,341 assets in September 2024 to 3,971 in September 2025 — an addition of 630 new assets in just one year.
  • TCR therapies rose from 506 assets to 592, with 86 new therapies entering development.
• Emerging Non-Oncology Applications: Beyond cancer, CAR therapies are increasingly being investigated in autoimmune and rare diseases, including systemic lupus erythematosus (SLE), systemic sclerosis, and myopathy.
• Clinical Development Hotspots:
  • The U.S. and Asia remain leading hubs for clinical trial initiations, while Europe continues to expand activity.
  • Notable in vivo CAR trials launched in 2025 include:
    • UB-VV111-01 (Umoja Biopharma, est. enrolment 106)
    • CPTX2309-01-01 (Umoja Biopharma, est. enrolment 38)
    • SPaCE-MT (Myeloid Therapeutics, est. enrolment 61)
• Deal-Making Momentum:
  Partnerships, acquisitions, and financings remain strong, with USD $9.44 billion in deal value recorded over the past year.
• Next-Generation Innovations:
  Advances such as armoured CARs and switch receptor technologies are reshaping the therapeutic potential of engineered immune cells.